NEWS - Jun 27, 2018 Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Read more
NEWS - Apr 3, 2018 Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer Read more
NEWS - Jan 17, 2018 Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System Read more
NEWS - Jan 9, 2018 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms Read more
NEWS - Oct 27, 2017 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms Read more
NEWS - Jun 28, 2017 Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program Read more
NEWS - Jun 21, 2017 Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics Read more
NEWS - Jun 15, 2017 Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors Read more
NEWS - May 18, 2017 Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company Read more
